Stenabolic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
=== Canada === In Canada, methadone can be prescribed in office settings and then picked up by patients at their local pharmacies. Regulations for methadone are made at the provincial level in Canada in comparison to the United States where much of the regulations comes from a federal level. While these offices offer counseling services, they are not required in order to receive methadone treatment. This practice coupled with methadone being accessible at community pharmacies makes the treatment more accessible to communities. In 1972, Canada's Narcotics Control Act prohibited the prescription of methadone to patients which stood in effect until 1996 when regulation of methadone became decentralized. Prescribers were still required to receive a federal exemption to prescribe methadone until 2018, during a spike in opioid overdose deaths, when the federal government removed this previously needed authorization. Nurse practitioners are also allowed to prescribe methadone in Canada. There is encouraged communication between the prescriber and pharmacist overseeing the treatment. Methadone will be denied to patients that show up to pharmacies visibly intoxicated or sedated state. In addition to pharmacies, methadone can be dispensed in assisted living facilities, long-term care facilities, and jails/prisons.
Dihydromorphine (Paramorfan, Paramorphan) is a semi-synthetic opioid structurally related to and derived from morphine. The 7,8-double bond in morphine is reduced to a single bond to get dihydromorphine. Dihydromorphine is a moderately strong analgesic and is used clinically in the treatment of pain and also is an active metabolite of the analgesic opioid drug dihydrocodeine. Dihydromorphine occurs in trace quantities in assays of opium on occasion, as does dihydrocodeine, dihydrothebaine, tetrahydrothebaine, etc. The process for manufacturing dihydromorphine from morphine for pharmaceutical use was developed in Germany in the late 19th century, with the synthesis being published in 1900 and the drug introduced clinically as Paramorfan shortly thereafter. A high-yield synthesis from tetrahydrothebaine was later developed.
Pulmonary disease: Pathophysiology: Due to vascular congestion in the lung, the pulmonary artery (Figure 3) becomes dilated and can compress the aorta and the LRLN. Primary pulmonary hypertension Pulmonary emboli Malignancy (pulmonary, mediastinal) Autoimmune: Mixed connective tissue disease Notable case: A young female with a history of mixed connective tissue disease presented with hoarseness of voice and was found to have secondary pulmonary artery hypertension. This was causing right heart enlargement and therefore compression of the LRLN. Idiopathic
=== Venous drainage === Unlike most of the myocardium, the SA node lacks large epicardial veins for blood return. Instead, its venous drainage is handled primarily by a network of small venules and sinusoids. These vessels, often referred to as Thebesian veins, drain deoxygenated blood directly into the right atrium. It is thought that this network provides a degree of protection for the node. This is because the vessels communicate with the nodal tissue and may help maintain viable conditions if the primary arterial supply is partially compromised.
Sources: en.wikipedia.org
=== Early life === Major Force is a product of the same U.S. Federal project which created Captain Atom during the Vietnam War. The government, in a project headed by Wade Eiling and the scientist Megala, experiments with the effects of atomic energy on an alien metal to determine its full protective abilities such as protecting a human being from a nuclear blast. After Nathaniel Adam's disappearance and the perceived failure of the Captain Atom Project, the government restarts the project with a new test subject named Clifford Zmeck and increased the amount of metal used. While in the Air Force, Zmeck is imprisoned on charges of rape and murder and sentenced to life in prison. However, he is offered a pardon in exchange for participation in the high-risk governmental experiment. Zmeck disappears into the Quantum Field, emerging one year after the return of Nathaniel Adam with abilities similar to his.
The hydroponic method of plant production by means of suspending the plant roots in a solution of nutrient-rich, oxygenated water. Traditional methods favor the use of plastic buckets and large containers with the plant contained in a net pot suspended from the centre of the lid and the roots suspended in the nutrient solution. The solution is oxygen saturated by an air pump combined with porous stones. With this method, the plants grow much faster because of the high amount of oxygen that the roots receive. The Kratky Method is similar to deep water culture, but uses a non-circulating water reservoir.
== Naming conventions == Before reunification, Germany was divided between the Bundesrepublik Deutschland (Federal Republic of Germany; commonly known as West Germany) and the Deutsche Demokratische Republik (DDR; German Democratic Republic; commonly known as East Germany). Reunification was achieved by accession (Beitritt) of the German Democratic Republic to the Federal Republic of Germany, so Bundesrepublik Deutschland became the official name of reunified Germany. In East Germany, the terms Westdeutschland (West Germany) or westdeutsche Bundesrepublik (West German Federal Republic) were preferred during the 1950s and 1960s. This changed under its constitutional amendment in 1974, when the idea of a single German nation was abandoned by East Germany. As a result, it officially considered West Germans and West Berliners as foreigners. The initialism BRD (FRG in English) began to prevail in East German usage in the early 1970s, beginning in the newspaper Neues Deutschland. Other Eastern Bloc nations soon followed suit. In 1965, the West German Federal Minister of All-German Affairs, Erich Mende, had issued the "Directives for the Appellation of Germany", recommending avoiding the initialism BRD. On 31 May 1974, the heads of West German federal and state governments recommended always using the full name in official publications. From then on, West German sources avoided the abbreviated form, with the exception of left-leaning organisations which embraced it.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.